# Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL

> **NCT05918276** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 24 (estimated)

## Conditions studied

- CLL/SLL

## Interventions

- **DRUG:** Orelabrutinib and BG

## Key facts

- **NCT ID:** NCT05918276
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07-15
- **Primary completion:** 2024-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05918276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05918276, "Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05918276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*